We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
Cap. Flow
+$511M
Cap. Flow %
4.78%
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$452M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$186M
3
CMMB
Chemomab Therapeutics
CMMB
+$128M
4
HAE icon
Haemonetics
HAE
+$105M
5
IRON icon
Disc Medicine
IRON
+$86.6M

Top Sells

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$369M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$319M
3
PFE icon
Pfizer
PFE
+$133M
4
BIIB icon
Biogen
BIIB
+$121M
5
CNC icon
Centene
CNC
+$120M

Sector Composition

Rank Sector Weight
1 Healthcare 94.88%
2 Technology 0.12%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
51
Mereo BioPharma
MREO
$49.4M
– –
0
– –
ORIC icon
52
Oric Pharmaceuticals
ORIC
$1.23B
$57.3M 0.54%
2,337,574
-584,393
-20% -$18.5M
DBTX
53
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$56.2M 0.53%
+4,945,192
New +$77.6M
ADVM
54
DELISTED
Adverum Biotechnologies
ADVM
$54.2M 0.51%
550,114
– –
OSH
55
DELISTED
Oak Street Health, Inc.
OSH
$52.5M 0.49%
967,000
+518,900
+116% +$28.9M
BNR
56
Burning Rock Biotech
BNR
$96.9M
$51.1M 0.48%
189,766
-226,402
-54% -$68.9M
TCDA
57
DELISTED
Tricida, Inc. Common Stock
TCDA
$50.9M 0.48%
9,614,280
– –
TMO icon
58
Thermo Fisher Scientific
TMO
$214B
$50.3M 0.47%
110,300
– –
ARCT icon
59
Arcturus Therapeutics
ARCT
$163M
$49.8M 0.47%
1,206,886
-73,200
-6% -$4.36M
CRIS icon
60
Curis
CRIS
$9.41M
$49.4M 0.46%
10,916
– –
APTO
61
DELISTED
Aptose Biosciences, Inc.
APTO
$48M 0.45%
17,844
– –
HARP
62
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$47.8M 0.45%
228,570
+45,000
+25% +$9.02M
CGEM icon
63
Cullinan Oncology
CGEM
$1.07B
$47.8M 0.45%
+1,146,145
New +$46.5M
VRNA
64
DELISTED
Verona Pharma
VRNA
$47.6M 0.45%
5,694,841
– –
TELA icon
65
TELA Bio
TELA
$30M
$45.1M 0.42%
3,027,542
– –
XENE icon
66
Xenon Pharmaceuticals
XENE
$6.28B
$44.7M 0.42%
2,497,917
– –
APLT
67
DELISTED
Applied Therapeutics
APLT
$42.3M 0.4%
2,257,387
+485,556
+27% +$10.5M
CRNX icon
68
Crinetics Pharmaceuticals
CRNX
$8.88B
$42.1M 0.39%
2,753,567
– –
SIBN icon
69
SI-BONE Inc
SIBN
$795M
$41.5M 0.39%
1,305,300
-63,200
-5% -$1.94M
NSTG
70
DELISTED
NanoString Technologies, Inc.
NSTG
$40.9M 0.38%
622,900
-1,004,000
-62% -$70.5M
MOH icon
71
Molina Healthcare
MOH
$10.5B
$38M 0.36%
162,400
– –
KALA icon
72
KALA BIO
KALA
$12.3M
$36.8M 0.34%
2,188
– –
VOR icon
73
Vor Biopharma
VOR
$1.08B
$35.9M 0.34%
+41,667
New +$35.3M
FUSN
74
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$34.6M 0.32%
3,224,770
– –
TRIL
75
DELISTED
Trillium Therapeutics Inc.
TRIL
$34M 0.32%
3,165,200
+205,000
+7% +$2.54M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2021 Portfolio in Review

As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.

  • OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
  • OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
  • OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
  • OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
  • OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
  • OrbiMed opened 39 new positions and closed 30 in Q1 2021.
  • OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.